Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The HIV-1 TAR RNA – Tat transactivation complex is a pivotal regulatory assembly essential for the high-level expression of the human immunodeficiency virus type 1 (HIV-1) genome [1, 11]. It is formed when the viral Trans-activator of transcription (Tat) protein binds to the Trans-activation response (TAR) element, a stable stem-loop RNA structure located at the 5' end of all nascent viral transcripts [11, 14]. This interaction serves as a molecular switch that recruits the host's positive transcription elongation factor b (P-TEFb) complex, comprising CDK9 and Cyclin T1, to the viral promoter [8, 12]. The recruitment of P-TEFb facilitates the phosphorylation of the RNA polymerase II C-terminal domain, thereby overcoming transcriptional pausing and promoting the synthesis of full-length viral RNAs [11, 13]. In the context of disease, the Tat-TAR complex is indispensable for viral replication and the progression of HIV-1 infection to AIDS [6, 10]. Because this interaction is unique to the virus and lacks a direct human homolog, it is an attractive target for the development of "block and lock" functional cure strategies [1, 8]. Therapeutic efforts focus on small molecules, cyclic peptides, and RNA-binding ligands designed to disrupt the binding interface, particularly at the TAR bulge or the Tat arginine-rich motif [1, 5, 14]. Inhibiting this complex effectively silences viral transcription, potentially preventing the reactivation of latent viral reservoirs and reducing the chronic inflammation associated with persistent Tat expression [1, 11].
Inhibition of the interaction between the HIV-1 Tat protein and the TAR RNA element to prevent the recruitment of the P-TEFb complex and subsequent transcriptional elongation of the viral genome.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HIV-1 TAR RNA – Tat transactivation complex (Tat-TAR complex) (Tat-TAR complex).